HCA HCA Healthcare, Inc. Common Stock
NYSE · Health Care · Wyświetl na SEC EDGAR ↗ zamknij Paź 6, 2026 10-K/10-Q Lip 28, 2026HCA Migawka akcji Cena, kapitalizacja rynkowa, P/E, EPS, ROE, zadłużenie/kapitał własny, zakres 52-tygodniowy
HCA Wykres ceny akcji Dzienny OHLCV ze wskaźnikami technicznymi — przesuwaj, powiększaj i dostosowuj widok
Granularność słupków dostosowuje się do wybranego okresu — najedź kursorem na wykres, aby zobaczyć otwarcia/maksima/minima/zamknięcia dla danego słupka.
O HCA Healthcare, Inc. Common Stock Przegląd firmy z Wikipedii
HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.
History
Early years
The Hospital Corporation of America (HCA) was founded in 1968 in Nashville, Tennessee, by Thomas F. Frist Sr., Thomas F. Frist Jr. and Jack C. Massey. The founders envisioned a company that would bring together hospitals to deliver patient-focused care while using the combined resources of the organization to strengthen hospitals and improve the practice of medicine. The company began with Nashville's Park View Hospital, which the elder Frist had founded in 1960 with other doctors and where he was chief executive.
The company included 11 hospitals when it filed its initial public offering on the New York Stock Exchange (NYSE) in 1969 and had 26 hospitals and 3,000 beds by the end of the year.
Growth and merger
The 1970s were characterized by rapid growth in the industry and for HCA Healthcare. In the early 1980s, the focus shifted to consolidation with HCA Healthcare acquiring General Care Corporation, General Health Services, Hospital Affiliates International and Health Care Corporation. By the end of 1981, the company operated 349 hospitals with more than 49,000 beds. Operating revenues had grown to $2.4 billion.
In 1987, HCA Healthcare, which had grown to operate 463 hospitals (255 owned and 208 managed), spun off HealthTrust, a privately owned, 104-hospital company. Believing its stock was undervalued, the company completed a $5.1 billion leveraged management buyout led by chairman Thomas F. Frist Jr. in 1988. HCA Healthcare re-emerged as a public company in 1992.
In February 1994, HCA Healthcare merged with Louisville, Kentucky-based Columbia Hospital Corporation, which earlier had acquired 73 hospitals of Galen Health Care from Humana,
to form Columbia/HCA Healthcare Corporation. Related names of note include HCA International and Health Corporation of America.
Columbia Hospital Corporation
In 1988, Rick Scott and Richard Rainwater each put up $125,000 in working capital in their new company, Columbia Hospital Corporation; they borrowed the remaining money needed to purchase two struggling hospitals in El Paso for $60 million. Then they acquired a neighboring hospital and shut it down. Within a year, the remaining two were doing much better. By the end of 1989, Columbia Hospital Corporation owned four hospitals with a total of 833 beds.
In 1992, Columbia made a stock purchase of Basic American Medical, which owned eight hospitals, primarily in southwestern Florida. In September 1993, Columbia did another stock purchase, worth $3.4 billion, of Galen Healthcare, which had been spun off by Humana Inc. several months earlier. At the time, Galen had approximately 90 hospitals. After the purchase, Galen stockholders had 82% of the stock in the combined company, with Scott still running the company.
Recent history
On November 17, 2006, HCA became a private company for the third time when it completed a merger in which the company was acquired by a private investor group including affiliates of Kohlberg Kravis Roberts and Bain Capital, together with Merrill Lynch and HCA Healthcare founder Thomas F. Frist Jr. The total transaction was valued at approximately $33 billion, making it the largest leveraged buyout in history at the time, eclipsing the 1989 buyout of RJR Nabisco.
In May 2010, HCA announced that the corporation would once again go public with an expected $4.6-billion IPO as HCA Holdings, Inc. In March 2011, HCA sold 126.2 million shares for $30 each, raising about $3.79 billion, at that time, the largest private-equity backed IPO in U.S. history. In May 2017, the corporation was renamed HCA Healthcare.
In December 2018, a historical marker was installed in the parking lot of HCA's Sarah Cannon Cancer Center in Nashville, formerly the location of HCA's first hospital, Park View Hospital.
In 2018, the company was ranked No. 67 in the 2019 Fortune 500 list of the largest United States corporations by total revenue.
In May 2021, the company finalized a deal with Google to develop healthcare algorithms using patient records. In August 2021, HCA announced a deal with venture capital firm General Catalyst to develop digital solutions to streamline workflows and improve patient care; as part of the deal, HCA sold its healthcare app development firm PatientKeeper to General Catalyst's portfolio company Commure.
In April 2022, HCA Healthcare announced a $1.5 million partnership with Florida International University's Nicole Wertheim college of Nursing and Health Sciences, to expand its facilities to address the national nursing shortage.
In October 2022, LCMC Health in partnership with Tulane University announced that it would acquire Tulane Medical Center, Lakeview Regional Medical Center, and Tulane Lakeside Hospital from HCA for $150 million pending regulatory approval.
In March 2024, it was announced HCA had completed the sale of West Hills Hospital and Medical Center and related assets in Los Angeles, California to UCLA Health, for an undisclosed amount.
Facilities
United States
As of 2024, HCA has 186 hospitals. They also report operating more than 2,400 additional sites of care, including surgery centers, freestanding ERs, urgent care centers, and physician clinics located in 20 U.S. states and in the United Kingdom. A significant portion of those hospitals are situated in Florida and Texas. As of 2022, HCA had 47 hospitals and 31 surgery centers in Florida, and 45 hospitals and 632 affiliated sites of care in Texas. In 2021, it announced plans to build 3 new hospitals in Florida. In 2022, The Dallas Morning News reported that HCA will build 5 new hospitals in Texas. They also have a strong presence in Tennessee, where it began. HCA had 13 hospitals there as of 2019.
Between 2003 and 2017, HCA did not enter any new markets. However, in July 2007, HCA sold its hospitals in Switzerland.
In 2017, HCA acquired the Memorial University Medical Center in Savannah, Georgia. That same year, they acquired three Houston, Texas, hospitals from Tenet Healthcare.
In 2019 they purchased Mission Health System which operates hospitals in North Carolina.
In January 2020, HCA Healthcare acquired Valify, a healthcare cost-management company. In May 2020, HCA acquired 49-bed Shands Starke (Fla.) Regional Medical Center and 25-bed Shands Live Oak (Fla.) Regional Medical Center from CHS. HCA is operating the two facilities as off-campus emergency departments of Lake City (Fla.) Medical Center and North Florida Regional Medical Center in Gainesville. Later that year, it signed an agreement to sell Garden Park Medical Center to Singing River Health System.
In 2021, HCA sold Redmond Regional Medical Center to AdventHealth for $635M, and four other Georgia hospitals to Piedmont Healthcare for $950 million. They also announced the acquisition of Meadows Regional Medical Center.
United Kingdom
HCA International, the UK arm of Hospital Corporation of America, "caters for around half of all private patients in London." The main hospital sites within the United Kingdom it operates include:
It opened urgent care walk-in centres at London Bridge Hospital and the Portland Hospital in March 2018. It claims that patients, on average, wait just seven minutes to see a nurse and 17 minutes to see a doctor. In February 2022, outsourced cleaning staff at London Bridge Hospital reported a lack of PPE, no access to sick pay, a lack of training and no prior warning about which rooms may be contaminated with the virus through the COVID-19 pandemic.
The Princess Grace Hospital specializes in breast cancer and surgery, aided by Kefah Mokbel and Nick Perry who, in 2005, founded The London Breast Institute.
The company opened The Harborne Hospital, a newly built private hospital located close to the Queen Elizabeth Hospital, Birmingham, in February 2024.
Significant areas of operation
Medical education
In recent years, HCA Healthcare has become a significant provider of clinical and medical education. It is the largest sponsor of graduate medical education programs in the U.S., with 56 teaching hospitals in 14 states, primarily in regions with a deficit of physician training programs. The company includes Research College of Nursing and Mercy School of Nursing, and has several advanced nursing simulation training centers. In early 2020, it completed the purchase of a majority stake in Galen College of Nursing, which operates 21 campuses in 12 states, offering Bachelor of Science and Associate of Science nursing degrees.
Controversies
Medicare billing practices lawsuit
In 1993, lawsuits were filed against HCA by former employees who alleged that the company had engaged in questionable Medicare billing practices. In 1997, with a federal investigation by the FBI, the IRS and the Department of Health and Human Services in its early stages, the Columbia/HCA board of directors forced Rick Scott to resign as chairman and CEO amid growing evidence that the company "had kept two sets of books, one to show the government and one with actual expenses listed." Thomas Frist, a co-founder of HCA and brother of U.S. Senator Bill Frist, returned to the company as CEO in 1997 and called on longtime friend and colleague Jack O. Bovender Jr. to help him turn the company around.
The federal probe culminated in 2003 with "the government receiving a total of over $2 billion in criminal fines and civil penalties for systematically defrauding federal health care programs." Columbia/HCA pleaded guilty to 14 felonies and admitted to systematically overcharging the government. The federal probe has been referred to as the longest and costliest investigation for health-care fraud in U.S. history.
2005 insider trading suit
In July 2005, U.S. Senator Bill Frist sold all of his HCA shares, which were held in a blind trust, two weeks before disappointing earnings sent the stock on a 9-point plunge. At the time, Frist was considering a run for president and said that he had sold his shares to avoid the appearance of a conflict of interest. When the company disclosed that other executives had also sold their shares during that same time, shareholders alleged that the company had made false claims about its profits to drive up the price, which then fell when the company reported disappointing financial results. Eleven of HCA's senior officers were sued for accounting fraud and insider trading. HCA settled the lawsuit in August 2007, agreeing to pay $20 million to the shareholders but admitting no wrongdoing, and no charges were brought.
COVID-19 PPE
During the COVID-19 pandemic in the United States, HCA hospital nurses and other workers spoke out about the lack of PPE. In April 2020, there was an outcry against HCA following the deaths of two nurses Celia Yap-Banago and Rosa Luna who worked at HCA hospitals in Kansas City and California and had contracted coronavirus, despite the alarm having been raised about the lack of PPE at work.
Mission Hospital Acquisition Complaints
On December 14, 2023, the North Carolina Attorney General sued HCA for violating the terms of an agreement that allowed HCA to purchase Mission Health.
On February 13, 2024, HCA Healthcare denied the allegations and asked a judge to dismiss the lawsuit by the Attorney General, and in return the hospital network filed a counterclaim against the Attorney General.
Źródło: Wikipedia (Angielski), CC BY-SA 4.0 · Zobacz w Wikipedii ↗
Wyniki 10-letnie Trendy przychodów, zysku netto, marż i EPS
Wycena Wskaźniki P/E, P/S, P/B, EV/EBITDA — czy akcje są drogie, czy tanie?
| Wskaźnik | Trend 5-letni | HCA | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| P/E (TTM) | 14.5średnia z 5 lat ≈13.8 | ≈13.8 | 16.5 | Niedowartościowany | |
| P/S (TTM) | 1.2średnia z 5 lat ≈1.2 | ≈1.2 | 1.3 | Niedowartościowany | |
| P/B (MRQ) | -14.2średnia z 5 lat ≈-39.2 | ≈-39.2 | · | · | |
| EV / EBITDA | 39.1średnia z 5 lat ≈37.3 | ≈37.3 | 19.6 | Zawyżona wycena | |
| Cena / FCF (TTM) | 15.7średnia z 5 lat ≈14.6 | ≈14.6 | · | · | |
| Cena / Przepływy pieniężne (TTM) | 8.5średnia z 5 lat ≈7.9 | ≈7.9 | 9.7 | Niedowartościowany | |
| EV / Revenue (EV / Przychody) | 1.8średnia z 5 lat ≈1.8 | ≈1.8 | · | · | |
| EV / FCF | 17.9średnia z 5 lat ≈21.8 | ≈21.8 | · | · | |
| PEG Ratio (Współczynnik PEG) | ≈0.7 | · | · | · |
Mediana porównawcza jest obliczana na znormalizowanej podstawie dla każdej metryki i może nie zawsze odpowiadać podstawie TTM/MRQ pokazanej dla tej akcji.
Rentowność Marże brutto, operacyjne i netto; ROE, ROA, ROIC
| Wskaźnik | Trend 5-letni | HCA | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| EBITDA Margin (Marża EBITDA) | 4.7%średnia z 5 lat ≈4.8% | ≈4.8% | 11.1% | Słaby | |
| Marża przed opodatkowaniem (TTM) | 12.7%średnia z 5 lat ≈13.6% | ≈13.6% | 9.8% | Najwyższa półka | |
| Marża Zysku Netto (TTM) | 8.8%średnia z 5 lat ≈9.3% | ≈9.3% | 7.3% | Zgodnie z | |
| ROA (TTM) | 11.1%średnia z 5 lat ≈11.2% | ≈11.2% | 6.5% | Najwyższa półka | |
| ROE (TTM) | -124.0%średnia z 5 lat ≈-963.7% | ≈-963.7% | 19.1% | Słaby |
Zdrowie finansowe Dług, płynność, wypłacalność — siła bilansu
| Wskaźnik | Trend 5-letni | HCA | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Dług / Kapitał Własny (MRQ) | -6.5średnia z 5 lat ≈-19.5 | ≈-19.5 | 0.2 | Niski dług | |
| Wskaźnik bieżący (MRQ) | 1.0średnia z 5 lat ≈1.2 | ≈1.2 | 1.2 | Niska płynność | |
| Quick Ratio (Wskaźnik Szybkości) | 0.7średnia z 5 lat ≈0.9 | ≈0.9 | 0.9 | Niska płynność | |
| Dług długoterminowy / Kapitał własny (MRQ) | -6.5średnia z 5 lat ≈-18.7 | ≈-18.7 | 0.2 | Niski dług |
Rozwój Wzrost przychodów, EPS i zysku netto: r/r, CAGR 3-letni, CAGR 5-letni
| Wskaźnik | Trend 5-letni | HCA | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Revenue YoY (Przychody R/R) | 7.1%średnia z 5 lat ≈8.0% | ≈8.0% | · | · | |
| Revenue CAGR 3Y (Przychody CAGR 3L) | 7.9%średnia z 5 lat ≈7.4% | ≈7.4% | · | · | |
| Revenue CAGR 5Y (Przychody CAGR 5L) | 8.0% | · | · | · | |
| EPS YoY | 28.8%średnia z 5 lat ≈25.6% | ≈25.6% | · | · | |
| Net Income YoY (Zysk Netto R/R) | 17.8%średnia z 5 lat ≈17.4% | ≈17.4% | · | · | |
| EPS CAGR 3Y (CAGR z EPS 3 lata) | 13.9%średnia z 5 lat ≈11.8% | ≈11.8% | · | · | |
| EPS CAGR 5Y (CAGR z EPS 5 lat) | 21.0% | · | · | · | |
| Net Income CAGR 3Y (CAGR z zysku netto 3 lata) | 6.3%średnia z 5 lat ≈4.0% | ≈4.0% | · | · | |
| Net Income CAGR 5Y (CAGR z zysku netto 5 lat) | 12.6% | · | · | · |
Efektywność kapitałowa Rotacja aktywów, rotacja zapasów, rotacja należności
| Wskaźnik | Trend 5-letni | HCA | średnia z 5 lat | Mediana porównawcza | Werdykt |
|---|---|---|---|---|---|
| Asset Turnover (Rotacja aktywów) | 1.3średnia z 5 lat ≈1.2 | ≈1.2 | 0.8 | Najwyższa półka | |
| Receivables Turnover (Rotacja należności) | 7.0średnia z 5 lat ≈7.1 | ≈7.1 | 8.4 | Słaby | |
| Revenue / Employee (Przychody / pracownika) | ≈$328.7K | · | · | · |
wartość · ≈ średnia z 5 lat · mediana branżowa · werdykt względem mediany
Dywidendy Stopa dywidendy, wskaźnik wypłaty, historia dywidend, 5-letni CAGR
| Data ex-dywidendy | Kwota | Waluta | Stopa zwrotu |
|---|---|---|---|
| Wrz 16, 2026 | $0,78 | USD | ≈0.71% |
| Cze 16, 2026 | $0,78 | USD | ≈0.76% |
| Mar 17, 2026 | $0,78 | USD | ≈0.58% |
| Gru 15, 2025 | $0,72 | USD | ≈0.60% |
| Wrz 16, 2025 | $0,72 | USD | ≈0.71% |
| Cze 16, 2025 | $0,72 | USD | ≈0.75% |
| Mar 17, 2025 | $0,72 | USD | ≈0.82% |
| Gru 13, 2024 | $0,66 | USD | ≈0.84% |
| Wrz 16, 2024 | $0,66 | USD | ≈0.64% |
| Cze 14, 2024 | $0,66 | USD | ≈0.75% |
| Mar 14, 2024 | $0,66 | USD | ≈0.76% |
| Gru 13, 2023 | $0,60 | USD | ≈0.89% |
| Wrz 14, 2023 | $0,60 | USD | ≈0.90% |
| Cze 15, 2023 | $0,60 | USD | ≈0.81% |
| Mar 16, 2023 | $0,60 | USD | ≈0.90% |
| Gru 13, 2022 | $0,56 | USD | ≈0.92% |
| Wrz 15, 2022 | $0,56 | USD | ≈1.0% |
| Cze 15, 2022 | $0,56 | USD | ≈1.1% |
| Mar 16, 2022 | $0,56 | USD | ≈0.75% |
| Gru 13, 2021 | $0,48 | USD | ≈0.90% |
Historia zysków EPS faktyczny vs szacowany, zaskoczenie %, wskaźnik trafień, data następnych wyników
| Okres | Raport | EPS Actual | EPS Szacowany | Niespodzianka |
|---|---|---|---|---|
| 30 czerwca 2026 | Lip 23, 2026 | $7.62 | $7.54 | 1.0% |
| 31 marca 2026 | $7.15 | $7.21 | -0.85% | |
| 31 grudnia 2025 | $8.14 | $7.53 | 8.0% | |
| 30 września 2025 | $6.96 | $5.77 | 20.6% | |
| 30 czerwca 2025 | $6.83 | $6.31 | 8.2% | |
| 31 marca 2025 | $6.45 | $5.84 | 10.5% |
Pełne podstawowe wskaźniki Wszystkie wskaźniki roczne — rachunek zysków i strat, bilans, przepływy pieniężne
Rachunek zysków i strat
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| SG&A Expense | $548M | $421M | $353M | $307M | $337M | $416M | $370M | $344M | $340M | $343M | |
| Operating Expenses | $65.77B | $62.08B | $57.26B | $51.65B | $48.92B | $46.10B | $46.09B | $41.34B | $39.23B | $36.68B | |
| Interest Expense | $2.25B | $2.06B | $1.94B | $1.74B | $1.57B | $1.58B | $1.82B | $1.75B | $1.69B | $1.71B | |
| Pretax Income | $9.83B | $8.52B | $7.71B | $8.58B | $9.83B | $5.43B | $5.24B | $5.33B | $4.38B | $4.81B | |
| Income Tax | $2.05B | $1.87B | $1.61B | $1.75B | $2.11B | $1.04B | $1.10B | $946M | $1.64B | $1.38B | |
| Net Income | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| EPS (Basic) | $28.70 | $22.27 | $19.25 | $19.43 | $21.52 | $11.10 | $10.27 | $10.90 | $6.12 | $7.53 | |
| EPS (Diluted) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 | |
| Shares (Basic) | 236,413,000 | 258,603,000 | 272,404,000 | 290,348,000 | 323,315,000 | 338,274,000 | 341,210,000 | 347,297,000 | 362,305,000 | 383,591,000 | |
| Shares (Diluted) | 239,495,000 | 261,806,000 | 276,412,000 | 294,666,000 | 328,752,000 | 343,605,000 | 348,226,000 | 355,303,000 | 372,221,000 | 395,851,000 | |
| EBITDA | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B |
Bilans
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.04B | $1.93B | $935M | $908M | $1.45B | $1.79B | $621M | $502M | $732M | $646M | |
| Short-term Investments | · | · | · | · | · | $116M | $147M | $47M | $54M | $49M | |
| Receivables | $10.87B | $10.75B | $9.96B | $8.89B | $8.10B | $7.05B | $7.38B | $6.79B | $6.50B | $5.83B | |
| Inventory | $1.65B | $1.74B | $2.02B | $2.07B | $1.99B | $2.02B | $1.85B | $1.73B | $1.57B | $1.50B | |
| Other Current Assets | $2.22B | $1.99B | $2.01B | $1.78B | $2.01B | $1.46B | $1.35B | $1.19B | $1.17B | $1.11B | |
| Current Assets | $15.78B | $16.41B | $14.93B | $13.64B | $13.54B | $12.33B | $11.20B | $10.21B | $9.98B | $9.09B | |
| PP&E (Net) | $31.14B | $29.41B | $27.71B | $25.57B | $24.06B | $23.20B | $22.71B | $19.76B | $17.89B | $16.35B | |
| PP&E (Gross) | $66.28B | $62.51B | $58.55B | $54.76B | $51.35B | $49.32B | $47.23B | $42.97B | $40.08B | $37.05B | |
| Accum. Depreciation | $35.13B | $33.10B | $30.83B | $29.18B | $27.29B | $26.12B | $24.52B | $23.21B | $22.19B | $20.70B | |
| Other Non-current Assets | $255M | $230M | $184M | $298M | $598M | $546M | $480M | $690M | $710M | $1.07B | |
| Total Assets | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Accounts Payable | $4.66B | $4.28B | $4.23B | $4.24B | $4.11B | $3.54B | $2.90B | $2.58B | $2.61B | $2.32B | |
| Current Liabilities | $16.35B | $15.18B | $12.65B | $9.90B | $9.58B | $8.70B | $7.76B | $7.57B | $6.16B | $5.83B | |
| Capital Leases | $1.85B | $1.86B | $1.90B | $1.75B | $1.75B | $1.67B | $1.50B | · | · | · | |
| Total Liabilities | · | · | · | · | · | · | $45.62B | $42.12B | $41.59B | $39.39B | |
| Long-term Debt | $44.28B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Total Debt | $41.60B | $43.03B | $39.59B | $38.08B | $34.58B | $31.00B | $33.72B | $32.82B | $33.06B | $31.38B | |
| Retained Earnings | $-5.72B | $-2.12B | $-1.35B | $-2.28B | $-532M | $777M | $-2.35B | $-4.57B | $-6.53B | $-6.97B | |
| AOCI | $-305M | $-387M | $-425M | $-490M | $-404M | $-502M | $-460M | $-381M | $-278M | $-338M | |
| Stockholders' Equity | $-6.03B | $-2.50B | $-1.77B | $-2.77B | $-933M | $572M | $-2.81B | $-4.95B | $-6.81B | $-7.30B | |
| Liabilities + Equity | $60.72B | $59.51B | $56.21B | $52.44B | $50.74B | $47.49B | $45.06B | $39.21B | $36.59B | $33.76B | |
| Shares Outstanding | 224,605,100 | 249,981,400 | 265,537,300 | 277,378,300 | 305,476,800 | 339,425,600 | 338,445,600 | 342,895,200 | 350,091,600 | 370,535,900 |
Przepływy pieniężne
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $3.52B | $3.31B | $3.08B | $2.97B | $2.85B | $2.72B | $2.60B | $2.28B | $2.13B | $1.97B | |
| Stock-based Comp | $401M | $360M | $262M | $341M | $440M | $362M | $347M | $268M | $270M | $251M | |
| Amort. of Intangibles | $12M | $16M | $20M | $44M | $25M | $26M | · | · | · | · | |
| Other Non-cash | $1.93B | $1.08B | $850M | $-431M | $-1.29B | $2.40B | $1.07B | $461M | $-3.53B | $-2.67B | |
| Operating Cash Flow | $12.64B | $10.51B | $9.43B | $8.52B | $8.96B | $9.23B | $7.60B | $6.76B | $5.43B | $5.65B | |
| CapEx | $4.94B | $4.88B | $4.74B | $4.39B | $3.58B | $2.83B | $4.16B | $3.57B | $3.02B | $2.76B | |
| Investing Cash Flow | $-4.99B | $-4.93B | $-5.32B | $-3.39B | $-2.64B | $-3.39B | $-5.72B | $-3.90B | $-4.28B | $-3.24B | |
| Debt Issued | $8.47B | $7.50B | $3.22B | $6.00B | $4.34B | $2.70B | $6.45B | $2.00B | $1.50B | $5.40B | |
| Net Debt Issued | $1.08B | $5.08B | $2.31B | $3.17B | $475M | $-737M | $1.13B | $296M | $749M | $925M | |
| Stock Repurchased | $10.07B | $6.04B | $3.81B | $7.00B | $8.21B | $441M | $1.03B | $1.53B | $2.05B | $2.75B | |
| Net Stock Activity | $-10.07B | $-6.04B | $-3.81B | $-7.00B | $-8.21B | $-441M | $-1.03B | $-1.53B | $-2.05B | $-2.75B | |
| Dividends Paid | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · | |
| Financing Cash Flow | $-8.55B | $-4.58B | $-4.09B | $-5.66B | $-6.66B | $-4.68B | $-1.77B | $-3.08B | $-1.06B | $-2.51B | |
| Net Change in Cash | $-893M | $998M | $27M | $-543M | $-342M | $1.17B | $119M | $-230M | $86M | $-95M | |
| Taxes Paid | $1.74B | $1.84B | $1.39B | $1.18B | $2.18B | $1.00B | $849M | $872M | $1.21B | $1.25B | |
| Free Cash Flow | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B | $6.40B | $3.44B | $3.19B | $2.41B | $2.89B | |
| Levered FCF | $5.91B | $4.03B | $3.16B | $2.74B | $4.15B | $5.12B | $2.00B | $1.74B | $1.35B | $1.68B |
Rentowność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 9.0% | 8.2% | 8.1% | 9.4% | 11.8% | 7.3% | 6.8% | 8.1% | · | · | |
| Pretax Margin | 13.0% | 12.1% | 11.9% | 14.2% | 16.7% | 10.5% | 10.2% | 11.4% | · | · | |
| EBITDA Margin | 4.7% | 4.7% | 4.7% | 4.9% | 4.9% | 5.3% | 5.1% | 4.9% | · | · | |
| ROA | 11.3% | 10.0% | 9.7% | 10.9% | 14.2% | 8.1% | 8.3% | 10.0% | 6.3% | 8.7% | |
| ROE | -159.1% | -269.6% | -230.9% | -305.0% | -3853.7% | -335.8% | -90.4% | -64.4% | -31.4% | -38.8% |
Płynność i wypłacalność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 | 1.4 | 1.4 | 1.3 | 1.6 | 1.6 | |
| Quick Ratio | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 | 1.0 | 1.1 | 1.0 | 1.2 | 1.1 | |
| Debt / Equity | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 | 54.2 | -12.0 | -6.6 | -4.9 | -4.3 | |
| LT Debt / Equity | -6.9 | -15.3 | -21.0 | -13.6 | -36.8 | 53.8 | -12.0 | -6.5 | -4.8 | -4.3 |
Efektywność
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.3 | 1.2 | 1.2 | 1.2 | 1.2 | 1.1 | 1.2 | 1.2 | · | · | |
| Receivables Turnover | 7.0 | 6.8 | 6.9 | 7.1 | 7.8 | 7.1 | 7.2 | 7.0 | · | · |
Na akcję
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-26.83 | $-10.00 | $-6.68 | $-9.98 | $-3.05 | $1.69 | $-8.30 | $-14.44 | $-19.44 | $-19.71 | |
| Revenue / Share | $315.66 | $269.68 | $235.04 | $204.41 | $178.71 | $149.98 | $147.42 | $131.37 | · | · | |
| Cash Flow / Share | $52.76 | $40.16 | $34.12 | $28.92 | $27.25 | $26.87 | $21.83 | $19.03 | $14.58 | $14.28 | |
| Cash / Share | $4.63 | $7.73 | $3.52 | $3.27 | $4.75 | $5.28 | $1.83 | $1.46 | $2.09 | $1.74 | |
| Dividend / Share | $2.88 | $2.64 | $2.40 | $2.24 | $1.92 | $0.43 | $1.60 | $1.40 | · | · | |
| EPS (TTM) | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 | $10.93 | $10.07 | $10.66 | $5.95 | $7.30 |
Stopy Wzrostu
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 7.1% | 8.7% | 7.9% | 2.5% | 14.0% | · | · | · | · | · | |
| Revenue CAGR 3Y | 7.9% | 6.3% | 8.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 8.0% | · | · | · | · | · | · | · | · | · | |
| EPS YoY | 28.8% | 16.0% | -0.94% | -9.5% | 93.6% | · | · | · | · | · | |
| EPS CAGR 3Y | 13.9% | 1.3% | 20.2% | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | 21.0% | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | 17.8% | 9.9% | -7.1% | -18.9% | 85.3% | · | · | · | · | · | |
| Net Income CAGR 3Y | 6.3% | -6.1% | 11.8% | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | 12.6% | · | · | · | · | · | · | · | · | · | |
| Dividends Paid CAGR 5Y | 34.7% | · | · | · | · | · | · | · | · | · |
Wycena (TTM)
| Wskaźnik | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B | $51.53B | $51.34B | $46.68B | $43.61B | $41.49B | |
| Net Income TTM | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B | $3.75B | $3.50B | $3.79B | $2.22B | $2.89B | |
| Market Cap | $104.86B | $75.03B | $71.88B | $66.56B | $78.48B | $55.82B | $50.03B | $42.67B | $30.75B | $27.43B | |
| Enterprise Value | $145.42B | $116.13B | $110.53B | $103.74B | $111.61B | $84.92B | $82.98B | $74.95B | $63.02B | $58.11B | |
| P/E | 16.5 | 13.6 | 14.3 | 12.5 | 12.1 | 15.0 | 14.7 | 11.7 | 14.8 | 10.1 | |
| P/S | 1.4 | 1.1 | 1.1 | 1.1 | 1.3 | 1.1 | 1.0 | 0.9 | 0.7 | 0.7 | |
| P/B | -17.4 | -30.0 | -40.5 | -24.1 | -84.1 | 97.6 | -17.8 | -8.6 | -4.5 | -3.8 | |
| P / Tangible Book | · | · | · | · | · | 97.6 | · | · | · | · | |
| P / Cash Flow | 8.3 | 7.1 | 7.6 | 7.8 | 8.8 | 6.0 | 6.6 | 6.3 | 5.7 | 4.9 | |
| P / FCF | 13.6 | 13.3 | 15.3 | 16.1 | 14.6 | 8.7 | 14.5 | 13.4 | 12.8 | 9.5 | |
| EV / EBITDA | 41.3 | 35.1 | 35.9 | 34.9 | 39.1 | 31.2 | 32.0 | 32.9 | 29.6 | 29.6 | |
| EV / FCF | 18.9 | 20.6 | 23.6 | 25.1 | 20.7 | 13.3 | 24.1 | 23.5 | 26.1 | 20.1 | |
| EV / Revenue | 1.9 | 1.6 | 1.7 | 1.7 | 1.9 | 1.6 | 1.6 | 1.6 | 1.4 | 1.4 | |
| Dividend Yield | 0.65% | 0.92% | 0.92% | 0.98% | 0.80% | 0.27% | 1.1% | 1.1% | 0.00% | · | |
| Earnings Yield | 6.1% | 7.3% | 7.0% | 8.0% | 8.2% | 6.7% | 6.8% | 8.6% | 6.8% | 9.9% | |
| Payout Ratio | 10.0% | 12.0% | 12.6% | 11.6% | 9.0% | 4.1% | 15.7% | 12.9% | · | · | |
| Annual Payout | $679M | $690M | $661M | $653M | $624M | $153M | $550M | $487M | $0 | · |
Rachunek zysków i strat
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $20.23B | $19.11B | $19.51B | $19.16B | $18.61B | $18.32B | $18.29B | $17.49B | $17.49B | $17.34B | $17.30B | $16.21B | $15.86B | $15.59B | $15.50B | $14.97B | |
| SG&A Expense | $148M | $133M | $153M | $139M | $130M | $126M | $120M | $111M | $100M | $90M | $108M | $89M | $82M | $74M | $79M | $74M | |
| Operating Expenses | $17.74B | $16.82B | $16.84B | $16.74B | $16.19B | $15.99B | $16.15B | $15.58B | $15.26B | $15.09B | $14.96B | $14.58B | $14.05B | $13.67B | $12.20B | $13.27B | |
| Interest Expense | $599M | $584M | $572M | $561M | $568M | $547M | $528M | $515M | $506M | $512M | $491M | $483M | $485M | $479M | $453M | $446M | |
| Pretax Income | $2.49B | $2.29B | $2.67B | $2.42B | $2.42B | $2.33B | $2.13B | $1.91B | $2.24B | $2.25B | $2.35B | $1.63B | $1.81B | $1.92B | $3.30B | $1.70B | |
| Income Tax | $564M | $430M | $509M | $515M | $524M | $502M | $447M | $424M | $550M | $445M | $484M | $355M | $397M | $379M | $656M | $360M | |
| Net Income | $1.70B | $1.62B | $1.88B | $1.64B | $1.65B | $1.61B | $1.44B | $1.27B | $1.46B | $1.59B | $1.61B | $1.08B | $1.19B | $1.36B | $2.08B | $1.13B | |
| EPS (Basic) | $7.70 | $7.25 | $8.22 | $7.05 | $6.91 | $6.52 | $5.72 | $4.94 | $5.60 | $6.01 | $6.00 | $3.98 | $4.35 | $4.92 | $7.30 | $3.97 | |
| EPS (Diluted) | $7.62 | $7.15 | $8.09 | $6.96 | $6.83 | $6.45 | $5.66 | $4.88 | $5.53 | $5.93 | $5.92 | $3.91 | $4.29 | $4.85 | $7.20 | $3.91 | |
| Shares (Basic) | 220,538,000 | 223,588,000 | · | 232,891,000 | 239,173,000 | 246,936,000 | · | 256,763,000 | 261,156,000 | 264,435,000 | · | 271,173,000 | 274,494,000 | 276,910,000 | · | 285,958,000 | |
| Shares (Diluted) | 222,828,000 | 226,652,000 | · | 236,181,000 | 241,911,000 | 249,440,000 | · | 259,917,000 | 264,071,000 | 268,016,000 | · | 275,424,000 | 278,198,000 | 280,961,000 | · | 289,852,000 | |
| EBITDA | $944M | $930M | · | $889M | $863M | $860M | · | $842M | $819M | $795M | · | $769M | $763M | $756M | · | $749M |
Bilans
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.01B | $940M | $1.04B | $997M | $939M | $1.06B | $1.93B | $2.89B | $831M | $1.28B | · | $891M | $862M | $842M | · | $999M | |
| Receivables | $12.28B | $11.32B | $10.87B | $10.43B | $10.46B | $11.09B | $10.75B | $9.91B | $10.24B | $10.04B | · | $9.18B | $8.71B | $8.66B | · | $8.55B | |
| Inventory | $1.66B | $1.68B | $1.65B | $1.73B | $1.79B | $1.79B | $1.74B | $1.78B | $1.80B | $1.90B | · | $2.03B | $2.05B | $2.08B | · | $2.01B | |
| Other Current Assets | $2.23B | $2.11B | $2.22B | $2.13B | $2.37B | $2.32B | $1.99B | $2.08B | $2.30B | $2.05B | · | $2.19B | $2.26B | $1.96B | · | $1.92B | |
| Current Assets | $17.19B | $16.05B | $15.78B | $15.29B | $15.56B | $16.26B | $16.41B | $16.66B | $15.17B | $15.28B | · | $14.29B | $13.89B | $13.54B | · | $13.48B | |
| PP&E (Net) | $31.82B | $31.47B | $31.14B | $30.57B | $30.12B | $29.74B | $29.41B | $29.05B | $28.64B | $28.10B | · | $27.12B | $26.64B | $26.05B | · | $24.98B | |
| PP&E (Gross) | $68.41B | $67.36B | $66.28B | $65.49B | $64.39B | $63.68B | $62.51B | $61.75B | $60.62B | $59.44B | · | $57.77B | $56.67B | $55.46B | · | $53.73B | |
| Accum. Depreciation | $36.59B | $35.89B | $35.13B | $34.92B | $34.27B | $33.94B | $33.10B | $32.70B | $31.99B | $31.34B | · | $30.66B | $30.02B | $29.41B | · | $28.75B | |
| Other Non-current Assets | $258M | $326M | $255M | $277M | $236M | $226M | $230M | $309M | $240M | $199M | · | $200M | $196M | $319M | · | $461M | |
| Total Assets | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | $56.21B | $54.59B | $53.59B | $52.71B | $52.44B | $51.48B | |
| Accounts Payable | $4.75B | $4.81B | $4.66B | $4.55B | $4.25B | $4.49B | $4.28B | $4.24B | $4.03B | $4.74B | · | $4.14B | $3.82B | $3.77B | · | $4.16B | |
| Current Liabilities | $17.31B | $19.26B | $16.35B | $17.90B | $15.94B | $13.63B | $15.18B | $14.90B | $14.30B | $13.14B | · | $12.41B | $11.54B | $11.03B | · | $9.78B | |
| Capital Leases | $1.83B | $1.82B | $1.85B | $1.84B | $1.88B | $1.86B | $1.86B | $1.92B | $1.89B | $1.91B | · | $1.78B | $1.81B | $1.72B | · | $1.76B | |
| Long-term Debt | $45.83B | $44.37B | $44.28B | $42.60B | $42.70B | $44.58B | $43.03B | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Total Debt | $43.45B | $39.49B | · | $38.40B | $39.38B | $44.58B | · | $42.97B | $40.88B | $40.19B | · | $39.35B | $38.93B | $38.86B | · | $37.71B | |
| Retained Earnings | $-6.31B | $-5.98B | $-5.72B | $-5.02B | $-4.09B | $-3.16B | $-2.12B | $-1.81B | $-1.17B | $-1.19B | · | $-1.99B | $-1.85B | $-2.03B | · | $-2.78B | |
| AOCI | $-334M | $-327M | $-305M | $-317M | $-309M | $-357M | $-387M | $-378M | $-433M | $-433M | $-425M | $-491M | $-456M | $-470M | $-490M | $-592M | |
| Stockholders' Equity | $-6.64B | $-6.30B | $-6.03B | $-5.33B | $-4.39B | $-3.52B | $-2.50B | $-2.18B | $-1.60B | $-1.61B | · | $-2.48B | $-2.30B | $-2.50B | · | $-3.37B | |
| Liabilities + Equity | $63.25B | $61.45B | $60.72B | $59.75B | $59.54B | $59.80B | $59.51B | $59.46B | $57.38B | $56.96B | · | $54.59B | $53.59B | $52.71B | · | $51.48B | |
| Shares Outstanding | 217,963,300 | 222,530,900 | 224,605,100 | 229,845,100 | 236,143,900 | 242,955,400 | 249,981,400 | 254,517,700 | 259,237,600 | 263,215,800 | · | 268,967,300 | 272,931,700 | 275,939,900 | · | 283,903,500 |
Przepływy pieniężne
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $944M | $930M | $911M | $889M | $863M | $860M | $856M | $842M | $819M | $795M | $789M | $769M | $763M | $756M | $750M | $749M | |
| Stock-based Comp | $85M | $86M | $100M | $104M | $99M | $98M | $85M | $76M | $112M | $87M | $57M | $72M | $56M | $77M | $83M | $87M | |
| Other Non-cash | · | $-622M | · | · | · | $-917M | · | · | · | $-4M | · | · | · | $-393M | · | · | |
| Operating Cash Flow | $2.33B | $2.01B | $2.36B | $4.42B | $4.21B | $1.65B | $2.56B | $3.52B | $1.97B | $2.47B | $2.67B | $2.48B | $2.48B | $1.80B | $2.53B | $3.02B | |
| CapEx | $1.23B | $1.12B | $1.49B | $1.29B | $1.18B | $991M | $1.28B | $1.19B | $1.28B | $1.12B | $1.16B | $1.15B | $1.24B | $1.20B | $1.32B | $1.13B | |
| Investing Cash Flow | $-1.56B | $-1.28B | $-1.32B | $-1.39B | $-1.25B | $-1.03B | $-1.35B | $-1.35B | $-1.33B | $-903M | $-1.60B | $-1.31B | $-1.26B | $-1.15B | $-793M | $-546M | |
| Debt Issued | $2.99B | $0 | $3.24B | $0 | $0 | $5.23B | $0 | $3.01B | $0 | $4.48B | $4M | $2M | $3.22B | $0 | $21M | $10M | |
| Net Debt Issued | · | $-58M | · | · | · | $1.34B | · | · | · | $2.42B | · | · | · | $-550M | · | · | |
| Stock Repurchased | $2.06B | $1.57B | $2.56B | $2.50B | $2.50B | $2.51B | $1.70B | $1.79B | $1.37B | $1.18B | $910M | $1.14B | $915M | $846M | $1.52B | $698M | |
| Net Stock Activity | · | $-1.57B | · | · | · | $-2.51B | · | · | · | $-1.18B | · | · | · | $-846M | · | · | |
| Dividends Paid | $171M | $183M | $162M | $166M | $171M | $180M | $165M | $169M | $171M | $185M | $160M | $162M | $164M | $175M | $156M | $160M | |
| Financing Cash Flow | $-704M | $-830M | $-999M | $-2.97B | $-3.09B | $-1.50B | $-2.16B | $-110M | $-1.09B | $-1.22B | $-1.04B | $-1.13B | $-1.20B | $-725M | $-1.84B | $-2.32B | |
| Net Change in Cash | $73M | $-100M | $43M | $58M | $-121M | $-873M | $-955M | $2.06B | $-453M | $349M | $44M | $29M | $20M | $-66M | $-91M | $141M | |
| Taxes Paid | $730M | $-5M | $1.51B | $81M | $136M | $10M | $358M | $487M | $998M | $1M | $316M | $297M | $766M | $7M | $244M | $322M | |
| Free Cash Flow | · | $895M | · | · | · | $660M | · | · | · | $1.35B | · | · | · | $606M | · | · | |
| Levered FCF | · | $421M | · | · | · | $231M | · | · | · | $940M | · | · | · | $221M | · | · |
Rentowność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 8.4% | 8.5% | · | 8.6% | 8.9% | 8.8% | · | 7.3% | 8.3% | 9.2% | · | 6.7% | 7.5% | 8.7% | · | 7.6% | |
| Pretax Margin | 12.3% | 12.0% | · | 12.6% | 13.0% | 12.7% | · | 10.9% | 12.8% | 13.0% | · | 10.1% | 11.4% | 12.3% | · | 11.4% | |
| EBITDA Margin | 4.7% | 4.9% | · | 4.6% | 4.6% | 4.7% | · | 4.8% | 4.7% | 4.6% | · | 4.7% | 4.8% | 4.9% | · | 5.0% | |
| ROA | 2.8% | 2.7% | · | 2.8% | 2.8% | 2.8% | · | 2.2% | 2.6% | 2.9% | · | 2.0% | 2.3% | 2.6% | · | 2.2% | |
| ROE | -30.8% | -33.0% | · | -43.7% | -55.2% | -62.7% | · | -54.5% | -74.9% | -77.4% | · | -36.9% | -39.9% | -60.2% | · | -55.8% |
Płynność i wypłacalność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.0 | 0.8 | · | 0.9 | 1.0 | 1.2 | · | 1.1 | 1.1 | 1.2 | · | 1.2 | 1.2 | 1.2 | · | 1.4 | |
| Quick Ratio | 0.8 | 0.6 | · | 0.6 | 0.7 | 0.9 | · | 0.9 | 0.8 | 0.9 | · | 0.8 | 0.8 | 0.9 | · | 1.0 | |
| Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -12.7 | · | -19.7 | -25.6 | -24.9 | · | -15.9 | -16.9 | -15.6 | · | -11.2 | |
| LT Debt / Equity | -6.5 | -6.3 | · | -7.2 | -9.0 | -11.7 | · | -17.5 | -22.7 | -23.0 | · | -14.9 | -15.9 | -14.6 | · | -11.1 |
Efektywność
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | |
| Receivables Turnover | 1.8 | 1.7 | · | 1.9 | 1.8 | 1.7 | · | 1.8 | 1.8 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 1.8 |
Na akcję
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-30.47 | $-28.32 | · | $-23.21 | $-18.61 | $-14.48 | · | $-8.57 | $-6.17 | $-6.14 | · | $-9.21 | $-8.44 | $-9.04 | · | $-11.87 | |
| Revenue / Share | $90.79 | $84.31 | · | $81.13 | $76.91 | $73.45 | · | $67.28 | $66.24 | $64.69 | · | $58.87 | $57.01 | $55.49 | · | $51.65 | |
| Cash Flow / Share | · | $8.89 | · | · | · | $6.62 | · | · | · | $9.21 | · | · | · | $6.42 | · | · | |
| Cash / Share | $4.65 | $4.22 | · | $4.34 | $3.98 | $4.36 | · | $11.35 | $3.21 | $4.88 | · | $3.31 | $3.16 | $3.05 | · | $3.52 | |
| Dividend / Share | $0.78 | $0.78 | $0.72 | $0.72 | $0.72 | $0.72 | $0.66 | $0.66 | $0.66 | $0.66 | $0.60 | $0.60 | $0.60 | $0.60 | $0.56 | $0.56 | |
| EPS (TTM) | $29.82 | $29.03 | · | $25.90 | $23.82 | $22.52 | · | $22.26 | $21.29 | $20.05 | · | $20.25 | $20.25 | $19.86 | · | $17.61 |
Wycena (TTM)
| Wskaźnik | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $78.01B | $76.39B | · | $74.37B | $72.70B | $71.58B | · | $69.62B | $68.35B | $66.72B | · | $63.16B | $61.92B | $60.88B | · | $59.80B | |
| Net Income TTM | $6.84B | $6.79B | · | $6.34B | $5.97B | $5.78B | · | $5.93B | $5.74B | $5.47B | · | $5.72B | $5.77B | $5.73B | · | $5.38B | |
| Market Cap | $84.98B | $105.31B | · | $97.96B | $90.47B | $83.95B | · | $103.44B | $83.29B | $87.79B | · | $66.16B | $82.83B | $72.76B | · | $52.18B | |
| Enterprise Value | $127.42B | $143.86B | · | $135.36B | $128.91B | $127.47B | · | $143.52B | $123.34B | $126.70B | · | $104.62B | $120.90B | $110.77B | · | $88.89B | |
| P/E | 13.1 | 16.3 | · | 16.5 | 16.1 | 15.3 | · | 18.3 | 15.1 | 16.6 | · | 12.1 | 15.0 | 13.3 | · | 10.4 | |
| P/S | 1.1 | 1.4 | · | 1.3 | 1.2 | 1.2 | · | 1.5 | 1.2 | 1.3 | · | 1.0 | 1.3 | 1.2 | · | 0.9 | |
| P/B | -12.8 | -16.7 | · | -18.4 | -20.6 | -23.9 | · | -47.4 | -52.1 | -54.4 | · | -26.7 | -36.0 | -29.2 | · | -15.5 | |
| P / Cash Flow | · | 52.3 | · | · | · | 50.8 | · | · | · | 35.6 | · | · | · | 40.4 | · | · | |
| EV / Revenue | 1.6 | 1.9 | · | 1.8 | 1.8 | 1.8 | · | 2.1 | 1.8 | 1.9 | · | 1.7 | 2.0 | 1.8 | · | 1.5 | |
| Dividend Yield | 0.80% | 0.65% | · | 0.70% | 0.76% | 0.82% | · | 0.66% | 0.81% | 0.76% | · | 0.99% | 0.79% | 0.89% | · | 1.2% | |
| Earnings Yield | 7.6% | 6.1% | · | 6.1% | 6.2% | 6.5% | · | 5.5% | 6.6% | 6.0% | · | 8.2% | 6.7% | 7.5% | · | 9.6% | |
| Payout Ratio | · | 11.3% | · | · | · | 11.2% | · | · | · | 11.6% | · | · | · | 12.8% | · | · | |
| Annual Payout | $682M | $682M | · | $682M | $685M | $685M | · | $685M | $678M | $671M | · | $657M | $655M | $651M | · | $645M |
Najnowszy okres po lewej · wartości null pokazane jako ·
Sprawozdania finansowe Rachunek zysków i strat, bilans, przepływy pieniężne — roczne, ostatnie 5 lat
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Przychody | $75.60B | $70.60B | $64.97B | $60.23B | $58.75B |
| Zysk netto | $6.78B | $5.76B | $5.24B | $5.64B | $6.96B |
| Rozwodniony EPS | $28.33 | $22.00 | $18.97 | $19.15 | $21.16 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Dług / Kapitał Własny | -6.9 | -17.2 | -22.3 | -13.8 | -37.1 |
| Wskaźnik bieżący | 1.0 | 1.1 | 1.2 | 1.4 | 1.4 |
| Wskaźnik Szybkości | 0.7 | 0.8 | 0.9 | 1.0 | 1.0 |
| Wskaźnik | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Wolny przepływ pieniężny | $7.69B | $5.64B | $4.69B | $4.13B | $5.38B |
Właściciele instytucjonalni (13F) 1 474 emitenci · $57.2B łącznie · Na dzień 30 września 2026
Instytucje, które zgłaszają posiadanie tych akcji w swoich kwartalnych zgłoszeniach SEC Form 13F. Tylko pozycje długie; pojedynczy zgłaszający może pojawić się dwukrotnie dla oddzielnych transz opcji. Duże przeciwstawne pozycje put/call zazwyczaj odzwierciedlają działalność market-makingową lub zabezpieczone zapasy, a nie przekonanie kierunkowe.
| Nowe pozycje | Zamknięte pozycje | Zwiększone | Zmniejszony | Zmiana liczby akcji netto |
|---|---|---|---|---|
| 121 (-64 vs poprzedni kw.) | 176 (+72 vs poprzedni kw.) | 458 (-25 vs poprzedni kw.) | 581 (+4 vs poprzedni kw.) | -627K |
Porównano z Q1 2026. Zgłoszenia SEC Form 13F są wymagane w ciągu 45 dni od końca kwartału plus krótki bufor dla spóźnionych zgłoszeń — kwartały mieszczące się jeszcze w tym terminie są pomijane na rzecz ostatniej w pełni zgłoszonej pary.
| Instytucja | Wartość | Akcje | % z śledzonych 13F | Typ |
|---|---|---|---|---|
| VANGUARD GROUP INC | $6 870 392 526 | 14 716 173 | 12,00% | Akcje |
| BlackRock, Inc. | $5 069 973 824 | 13 003 600 | 8,86% | Akcje |
| VANGUARD CAPITAL MANAGEMENT LLC | $3 954 150 533 | 10 141 708 | 6,91% | Akcje |
| Sanders Capital, LLC | $3 442 060 818 | 8 828 287 | 6,01% | Akcje |
| STATE STREET CORP | $2 912 102 056 | 7 469 035 | 5,09% | Akcje |
| WELLINGTON MANAGEMENT GROUP LLP | $1 835 396 649 | 4 707 473 | 3,21% | Akcje |
| GEODE CAPITAL MANAGEMENT, LLC | $1 423 654 808 | 3 668 008 | 2,49% | Akcje |
| First Eagle Investment Management, LLC | $1 284 907 912 | 3 295 565 | 2,24% | Akcje |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1 057 704 509 | 2 712 828 | 1,85% | Akcje |
| MORGAN STANLEY | $1 008 556 857 | 2 586 771 | 1,76% | Akcje |
| GOLDMAN SACHS GROUP INC | $960 811 481 | 2 464 314 | 1,68% | Akcje |
| JPMORGAN CHASE & CO | $896 800 955 | 2 285 832 | 1,57% | Akcje |
| ARROWSTREET CAPITAL, LIMITED PARTNERSHIP | $861 456 107 | 2 209 485 | 1,50% | Akcje |
| NORGES BANK | $836 457 140 | 2 145 367 | 1,46% | Akcje |
| Capital World Investors | $770 864 224 | 1 977 121 | 1,35% | Akcje |
| Capital International Investors | $747 403 041 | 1 916 947 | 1,31% | Akcje |
| UBS AM, a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC | $709 859 997 | 1 500 000 | 1,24% | Akcje |
| NORTHERN TRUST CORP | $666 150 458 | 1 708 560 | 1,16% | Akcje |
| FMR LLC | $636 503 475 | 1 632 520 | 1,11% | Akcje |
| Invesco Ltd. | $596 390 232 | 1 529 637 | 1,04% | Akcje |
| NORDEA INVESTMENT MANAGEMENT AB | $553 702 529 | 1 429 943 | 0,97% | Akcje |
| BARCLAYS PLC | $514 349 127 | 1 319 216 | 0,90% | Akcje |
| JANUS HENDERSON GROUP PLC | $481 486 890 | 1 017 441 | 0,84% | Akcje |
| Crake Asset Management LLP | $449 072 183 | 1 151 792 | 0,78% | Akcje |
| Metropolis Capital Ltd | $430 915 307 | 910 564 | 0,75% | Akcje |
| Darsana Capital Partners LP | $428 879 000 | 1 100 000 | 0,75% | Akcje |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $414 565 358 | 1 063 288 | 0,72% | Akcje |
| Legal & General Group Plc | $410 992 402 | 1 054 124 | 0,72% | Akcje |
| FRANKLIN RESOURCES INC | $399 958 688 | 1 025 824 | 0,70% | Akcje |
| Life Cycle Investment Partners Ltd | $355 737 196 | 912 404 | 0,62% | Akcje |
| Bank of New York Mellon Corp | $350 359 895 | 898 612 | 0,61% | Akcje |
| VANGUARD FIDUCIARY TRUST CO | $339 685 814 | 871 235 | 0,59% | Akcje |
| ROYAL BANK OF CANADA | $320 194 000 | 821 241 | 0,56% | Akcje |
| LYRICAL ASSET MANAGEMENT LP | $255 015 742 | 654 071 | 0,45% | Akcje |
| BANK OF AMERICA CORP /DE/ | $238 456 934 | 611 601 | 0,42% | Akcje |
| SCHRODER INVESTMENT MANAGEMENT GROUP | $237 236 367 | 608 470 | 0,41% | Akcje |
| ROYAL LONDON ASSET MANAGEMENT LTD | $235 649 908 | 604 401 | 0,41% | Akcje |
| PRINCIPAL FINANCIAL GROUP INC | $234 827 401 | 602 290 | 0,41% | Akcje |
| UBS Group AG | $230 953 291 | 592 355 | 0,40% | Akcje |
| National Pension Service | $230 650 346 | 591 578 | 0,40% | Akcje |
| Russell Investments Group, Ltd. | $206 832 565 | 530 340 | 0,36% | Akcje |
| Nuveen, LLC | $199 595 109 | 511 927 | 0,35% | Akcje |
| Gobi Capital LLC | $195 742 325 | 502 045 | 0,34% | Akcje |
| Cryder Capital Partners LLP | $194 561 738 | 499 017 | 0,34% | Akcje |
| Allianz Asset Management GmbH | $181 127 299 | 464 560 | 0,32% | Akcje |
| DEUTSCHE BANK AG\ | $175 985 429 | 451 372 | 0,31% | Akcje |
| Swiss National Bank | $172 097 446 | 441 400 | 0,30% | Akcje |
| DIMENSIONAL FUND ADVISORS LP | $172 079 393 | 441 313 | 0,30% | Akcje |
| AustralianSuper Pty Ltd | $159 635 782 | 409 438 | 0,28% | Akcje |
| HSBC HOLDINGS PLC | $158 555 065 | 406 750 | 0,28% | Akcje |
Aktywiści i właściciele 5%+ 4 akcje
Inwestorzy, którzy złożyli SEC Schedule 13D — posiadanie beneficjentów powyżej 5% z zamiarem wpływania na emitenta (udziały aktywistów, kampanie zarządu, M&A). Każdy wiersz pokazuje najnowszy znany stan pozycji tego zgłaszającego.
| Zgłaszający | Złożono | Udział | Status | Cel | Zgłoszenie |
|---|---|---|---|---|---|
| Frisco Holding II, Hercules Holding II, Thomas F. Frist, Jr., Thomas F. Frist III, William R. Frist, Patricia F. Elcan | 10 lutego 2026 | 31,60% | Pierwotne zgłoszenie | · | SEC |
| 22 listopada 2006 | · | Pierwotne zgłoszenie | · | SEC | |
| Merrill Lynch Bank USA | 11 września 2006 | · | Pierwotne zgłoszenie | · | SEC |
| Frisco, Inc., Frisco Partners, Thomas F. Frist, Jr., Patricia Champion Frist, Patricia Frist Elcan, William Robert Frist, Thomas F. Frist III, Merrill Lynch Professional Clearing Corp., Merrill Lynch, Pierce, Fenner & Smith Incorporated, Merrill Lynch Financial Markets, Inc., Merrill Lynch International, Merrill Lynch & Co., Inc., Merrill Lynch Trust Company, FSB, Citigroup Inc.*, Bank of America Corporation, NB Holdings Corporation, NationsBanc Montgomery Holdings Corporation, Banc of America Securities LLC | 4 sierpnia 2006 | · | Pierwotne zgłoszenie | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Insiderzy spółki 92 insiderów · 54 dyrektorzy generalni · 31 dyrektorzy
| Insider | Rola | Ostatnia aktywność | Posiadane akcje | Kupna 12m | Sprzedaże 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Samuel N Hazen | CEO | 10 lutego 2026 F | 64 842 | 0 | 7 | $-21 483 290 |
| O'Boyle Michael P | President & CEO - Parallon | 26 lutego 2013 A | 21 429 | 0 | 0 | $0 |
| Mike A Marks | EVP and CFO | 7 maja 2026 G | 46 576 | 0 | 0 | $0 |
| Bill B Rutherford | CFO and EVP | 16 lutego 2024 F | 22 251 | 0 | 0 | $0 |
| Russell K Harms | CFO - Central Group | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Robert Samuel Hankins JR | CFO-Outpatient Services Group | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Richard J Shallcross | CFO - Western Group | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Jeffrey T Crudele | CFO-Eastern Division | 1 lipca 2005 F | 13 865 | 0 | 0 | $0 |
| Erol R Akdamar | Group President | 12 listopada 2024 M | 6 843 | 0 | 0 | $0 |
| Timothy M Mcmanus | Group President | 31 lipca 2024 M | 27 008 | 0 | 0 | $0 |
| Richard A Hammett | Group President | 16 lutego 2024 F | 17 936 | 0 | 0 | $0 |
| Charles J Hall | Group President | 11 listopada 2022 M | 202 443 | 0 | 0 | $0 |
| Bruce A Moore JR | Group President - Service Line | 11 listopada 2022 S | 30 807 | 0 | 0 | $0 |
| Paul W Rutledge | Group President | 31 grudnia 2012 A | 335 657 | 0 | 0 | $0 |
| Beverly B Wallace | President - Parallon | 2 listopada 2011 M | 144 714 | 0 | 0 | $0 |
| Charles Robert Evans | President - Eastern Group | 26 lipca 2006 A | 62 173 | 0 | 0 | $0 |
| Marilyn B Tavenner | President-Outpatient Svcs Grp | 27 października 2005 A | 26 154 | 0 | 0 | $0 |
| Greg Roth | President-Ambulatory Surgery | 31 października 2004 D | 9 029 | 0 | 0 | $0 |
| Jay Grinney | President-Eastern Group | 7 maja 2004 D | 24 177 | 0 | 0 | $0 |
| Jon M Foster | EVP and COO | 10 lutego 2026 F | 23 062 | 0 | 0 | $0 |
| Michael R Mcalevey | EVP & Chief Legal & Admin Off. | 26 sierpnia 2026 J | 0 | 0 | 2 | $-2 747 520 |
| Jennifer Berres | SVP & Chief Human Res. Officer | 11 lutego 2026 S | 11 993 | 0 | 2 | $-4 126 932 |
| Christopher F. Wyatt | SVP & Controller | 11 lutego 2026 S | 44 379 | 0 | 1 | $-2 020 000 |
| Erica Rossitto | SVP & Chief Nurse Executive | 10 lutego 2026 F | 10 407 | 0 | 0 | $0 |
| Michael S. Cuffe | EVP and Chief Clinical Officer | 10 lutego 2026 F | 32 080 | 0 | 1 | $-747 135 |
| Sammie S Mosier | SVP & Chief Nurse Executive | 13 lutego 2025 F | 11 113 | 0 | 0 | $0 |
| Kathleen M Whalen | SVP & Chief Ethics Officer | 14 listopada 2024 S | 9 454 | 0 | 0 | $0 |
| Phillip G Billington | SVP-Internal Audit Services | 12 listopada 2024 M | 52 702 | 0 | 0 | $0 |
| Joseph A Sowell III | SVP; Chief Development Officer | 5 sierpnia 2024 G | 18 526 | 0 | 0 | $0 |
| Deborah M Reiner | SVP - Mktg. & Communications | 29 lipca 2024 S | 3 510 | 0 | 0 | $0 |
| Kathryn A. Torres | SVP-Payer Contracting & Align. | 25 lipca 2024 S | 17 755 | 0 | 0 | $0 |
| Jeffrey E. Cohen | SVP-Government Relations | 9 maja 2024 S | 5 185 | 0 | 0 | $0 |
| Chad J Wasserman | SVP and CIO | 18 marca 2024 M | 1 576 | 0 | 0 | $0 |
| Martin P. Paslick | SVP and CIO | 12 kwietnia 2023 M | 24 643 | 0 | 0 | $0 |
| Jane D. Englebright | SVP and Chief Nursing Officer | 9 listopada 2021 S | 0 | 0 | 0 | $0 |
| Robert A Waterman | SVP & General Counsel | 5 maja 2021 S | 50 062 | 0 | 0 | $0 |
| William J Morrow | SVP - Finance and Treasurer | 18 lutego 2021 F | 5 578 | 0 | 0 | $0 |
| Sandra L. Morgan | SVP-Provider Relations | 18 lutego 2021 F | 10 122 | 0 | 0 | $0 |
| Victor L Campbell | SVP-Government Affairs | 1 maja 2019 A | 194 145 | 0 | 0 | $0 |
| John M Steele | SVP & Chief Human Res. Officer | 25 lutego 2019 M | 84 157 | 0 | 0 | $0 |
| Milton R Johnson | Chairman | 25 lutego 2019 M | 881 823 | 0 | 0 | $0 |
| Ravi S. Chari | SVP-Clinical Excellence | 25 lutego 2018 M | 7 003 | 0 | 0 | $0 |
| Alan R Yuspeh | SVP & Chief Ethics Officer | 25 lutego 2018 M | 35 546 | 0 | 0 | $0 |
| Joseph N Steakley | SVP-Internal Audit Services | 25 lutego 2018 M | 65 199 | 0 | 0 | $0 |
| Jana Joustra Davis | SVP - Mktg. & Corp. Affairs | 23 maja 2017 M | 26 378 | 0 | 0 | $0 |
| David Gwin Anderson | SVP - Finance | 7 listopada 2016 M | 110 167 | 0 | 0 | $0 |
| Donald W Stinnett | SVP & Controller | 25 lutego 2016 A | 51 965 | 0 | 0 | $0 |
| Noel B Williams | SVP and CIO | 16 maja 2012 M | 299 030 | 0 | 0 | $0 |
| Jack O Bovender JR | Chairman | 6 października 2009 A | 188 340 | 0 | 0 | $0 |
| Carl V George | SVP - Development | 27 lutego 2009 M | 13 092 | 0 | 0 | $0 |
| Patricia T Lindler | SVP - Government Programs | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Rosalyn S Elton | SVP-Operations Finance | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Frank M Houser MD | SVP-Quality & Medical Director | 26 lipca 2006 A | 46 145 | 0 | 0 | $0 |
| James A Fitzgerald JR | SVP-Supply Chain Operations | 29 stycznia 2006 F | 20 674 | 0 | 0 | $0 |
| Andrea B Smith | Dyrektor | 28 kwietnia 2026 A | 4 666 | 0 | 0 | $0 |
| William R Frist | Dyrektor | 28 kwietnia 2026 A | 13 740 | 0 | 0 | $0 |
| Wayne Joseph Riley | Dyrektor | 28 kwietnia 2026 A | 15 029 | 0 | 0 | $0 |
| Hugh F Johnston | Dyrektor | 28 kwietnia 2026 A | 4 475 | 0 | 0 | $0 |
| Thomas F Frist III | Dyrektor | 28 kwietnia 2026 A | 15 858 | 0 | 0 | $0 |
| Michael W Michelson | Dyrektor | 28 kwietnia 2026 A | 12 576 | 0 | 0 | $0 |
| Nancy Ann Deparle | Dyrektor | 28 kwietnia 2026 A | 21 910 | 0 | 0 | $0 |
| John Chidsey | Dyrektor | 28 kwietnia 2026 A | 1 305 | 0 | 0 | $0 |
| Robert J Dennis | Dyrektor | 29 kwietnia 2025 A | 26 601 | 0 | 0 | $0 |
| Meg Crofton | Dyrektor | 29 kwietnia 2024 A | 6 331 | 0 | 0 | $0 |
| Charles O Holliday JR | Dyrektor | 25 kwietnia 2022 A | 18 955 | 0 | 0 | $0 |
| Geoffrey G Meyers | Dyrektor | 1 maja 2019 A | 39 153 | 0 | 0 | $0 |
| John W Rowe | Dyrektor | 1 maja 2019 A | 30 388 | 0 | 0 | $0 |
| Ann H Lamont | Dyrektor | 2 maja 2018 A | 17 661 | 0 | 0 | $0 |
| Jay O Light | Dyrektor | 3 maja 2017 A | 30 953 | 0 | 0 | $0 |
| Stephen G Pagliuca | Dyrektor | 5 grudnia 2014 D | 7 612 921 | 0 | 0 | $0 |
| Christopher R Gordon | Dyrektor | 1 listopada 2013 D | 30 003 156 | 0 | 0 | $0 |
| John Connaughton | Dyrektor | 1 listopada 2013 D | 30 003 156 | 0 | 0 | $0 |
| John H Mcarthur | Dyrektor | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Kent C Nelson | Dyrektor | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Magdalena Averhoff MD | Dyrektor | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Glenda A Hatchett | Dyrektor | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Frederick W Gluck | Dyrektor | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Harold T Shapiro | Dyrektor | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Michael C Armstrong | Dyrektor | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Martin Feldstein | Dyrektor | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Michael T Long | Dyrektor | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| ROYAL FRANK S | Dyrektor | 17 listopada 2006 D | 0 | 0 | 0 | $0 |
| Patricia F Elcan | Posiadacz 10% | 6 lutego 2026 J | 36 557 141 | 0 | 0 | $0 |
| Frisco Holding II | Posiadacz 10% | 6 lutego 2026 J | 36 557 141 | 0 | 0 | $0 |
| HERCULES HOLDING II, LLC | Posiadacz 10% | 6 lutego 2026 J | 32 282 889 | 0 | 0 | $0 |
| Thomas F Frist JR | Posiadacz 10% | 6 lutego 2026 J | 36 557 141 | 0 | 0 | $0 |
| Patricia C Frist | Posiadacz 10% | 20 lutego 2018 G | 0 | 0 | 0 | $0 |
| KKR PEI GP LTD | Posiadacz 10% | 1 kwietnia 2014 J | 0 | 0 | 0 | $0 |
| Jonathan B Perlin | · | 2 sierpnia 2021 S | 44 348 | 0 | 0 | $0 |
| Juan Vallarino | · | 9 maja 2016 M | 61 036 | 0 | 0 | $0 |
| Richard M Bracken | · | 31 grudnia 2014 F | 82 499 | 0 | 0 | $0 |
| BANK OF AMERICA CORP /DE/ | · | 6 listopada 2012 S | 2 652 364 | 0 | 0 | $0 |
Insiderzy z zgłoszeń SEC Form 3/4/5; netto = tylko otwarty rynek P/S
Posiadanie ETF-ów Posiadane przez 141 funduszy ETF
Waga odzwierciedla wyłącznie bezpośrednie udziały kapitałowe (N-PORT); fundusze oparte na dźwigni lub instrumentach pochodnych mogą posiadać dodatkowe ekspozycje na swapy, które nie są pokazane.
| Fundusz | Waga | Jednostki | Na dzień | Źródło |
|---|---|---|---|---|
| BUL · Pacer Funds Trust | 5,07% | 16 545 NS | 31 lipca 2026 | N-PORT |
| IHF · iShares Trust | 4,75% | 147 977 SH | 11 września 2026 | Dziennie |
| STNC · Hennessy Funds Trust | 3,17% | 7 315 NS | 31 lipca 2026 | N-PORT |
| PKW · Invesco Exchange-Traded Fund Trust | 2,47% | 97 151 SH | 5 października 2026 | Dziennie |
| COWZ · Pacer Funds Trust | 2,07% | 960 711 NS | 31 lipca 2026 | N-PORT |
| WLTG · ETF Opportunities Trust | 2,06% | 3 942 NS | 31 lipca 2026 | N-PORT |
| RSPH · Invesco Exchange-Traded Fund Trust | 1,67% | 34 181 SH | 5 października 2026 | Dziennie |
| RPG · Invesco Exchange-Traded Fund Trust | 1,27% | 58 310 SH | 5 października 2026 | Dziennie |
| FLAG · Global X Funds | 1,14% | 48 NS | 31 lipca 2026 | N-PORT |
| FCPI · FIDELITY COVINGTON TRUST | 1,03% | 6 909 NS | 31 lipca 2026 | N-PORT |
| IYH · iShares Trust | 1,01% | 87 417 SH | 11 września 2026 | Dziennie |
| SRHQ · Elevation Series Trust | 0,94% | 4 938 NS | 31 lipca 2026 | N-PORT |
| NEAR · iShares U.S. ETF Trust | 0,92% | 48 109 000 SH | 11 września 2026 | Dziennie |
| FHLC · FIDELITY COVINGTON TRUST | 0,91% | 74 445 NS | 31 lipca 2026 | N-PORT |
| VHT · VANGUARD WORLD FUND | 0,90% | 470 451 SH | 19 sierpnia 2026 | Dziennie |
| FXH · First Trust Exchange-Traded AlphaDE… | 0,87% | 22 725 NS | 31 lipca 2026 | N-PORT |
| DIVB · iShares Trust | 0,87% | 42 100 SH | 11 września 2026 | Dziennie |
| NFRA · FlexShares Trust | 0,84% | 62 628 NS | 31 lipca 2026 | N-PORT |
| IXJ · iShares Trust | 0,83% | 81 708 SH | 11 września 2026 | Dziennie |
| SPVM · Invesco Exchange-Traded Fund Trust | 0,80% | 2 483 SH | 5 października 2026 | Dziennie |
| QUVU · Hartford Funds Exchange-Traded Trust | 0,79% | 3 522 NS | 31 lipca 2026 | N-PORT |
| BSCT · Invesco Exchange-Traded Self-Indexe… | 0,78% | 23 458 000 | 5 października 2026 | Dziennie |
| BSCS · Invesco Exchange-Traded Self-Indexe… | 0,74% | 25 787 000 | 5 października 2026 | Dziennie |
| CURE · Direxion Shares ETF Trust | 0,72% | 3 056 NS | 31 lipca 2026 | N-PORT |
| VFMF · VANGUARD WELLINGTON FUND | 0,67% | 12 075 SH | 19 sierpnia 2026 | Dziennie |
| LGDX · Tidal Trust III | 0,66% | 2 345 NS | 31 lipca 2026 | N-PORT |
| VFVA · VANGUARD WELLINGTON FUND | 0,55% | 11 876 SH | 19 sierpnia 2026 | Dziennie |
| BSCR · Invesco Exchange-Traded Self-Indexe… | 0,50% | 22 854 000 | 5 października 2026 | Dziennie |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0,46% | 7 404 NS | 31 lipca 2026 | N-PORT |
| WLDR · Two Roads Shared Trust | 0,43% | 964 NS | 31 lipca 2026 | N-PORT |
| ROUS · Lattice Strategies Trust | 0,42% | 7 289 NS | 31 lipca 2026 | N-PORT |
| RWL · Invesco Exchange-Traded Fund Trust … | 0,40% | 92 347 SH | 5 października 2026 | Dziennie |
| QLC · FlexShares Trust | 0,39% | 9 856 NS | 31 lipca 2026 | N-PORT |
| XOEF · iShares Trust | 0,37% | 194 SH | 11 września 2026 | Dziennie |
| GSY · Invesco Actively Managed Exchange-T… | 0,36% | 14 000 000 | 5 października 2026 | Dziennie |
| UPSD · ETF Series Solutions | 0,33% | 972 NS | 31 lipca 2026 | N-PORT |
| BSCU · Invesco Exchange-Traded Self-Indexe… | 0,33% | 9 324 000 | 5 października 2026 | Dziennie |
| MGV · VANGUARD WORLD FUND | 0,29% | 97 604 SH | 19 sierpnia 2026 | Dziennie |
| PFIG · Invesco Exchange-Traded Fund Trust … | 0,28% | 390 000 | 2 października 2026 | Dziennie |
| JPUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,28% | 3 186 NS | 31 lipca 2026 | N-PORT |
| USXF · iShares Trust | 0,26% | 9 226 SH | 11 września 2026 | Dziennie |
| IUS · Invesco Exchange-Traded Self-Indexe… | 0,26% | 5 813 SH | 5 października 2026 | Dziennie |
| IWX · iShares Trust | 0,23% | 21 535 SH | 11 września 2026 | Dziennie |
| VTV · VANGUARD INDEX FUNDS | 0,23% | 1 475 731 SH | 19 sierpnia 2026 | Dziennie |
| JMOM · J.P. Morgan Exchange-Traded Fund Tr… | 0,23% | 14 235 NS | 31 lipca 2026 | N-PORT |
| MPLY · Strategy Shares | 0,22% | 87 NS | 31 lipca 2026 | N-PORT |
| EUSA · iShares, Inc. | 0,21% | 9 589 SH | 11 września 2026 | Dziennie |
| RSP · Invesco Exchange-Traded Fund Trust | 0,21% | 461 214 SH | 5 października 2026 | Dziennie |
| FTC · First Trust Exchange-Traded AlphaDE… | 0,20% | 6 420 NS | 31 lipca 2026 | N-PORT |
| SIZE · iShares Trust | 0,19% | 1 920 SH | 11 września 2026 | Dziennie |
| DYNF · BlackRock ETF Trust | 0,19% | 183 934 SH | 11 września 2026 | Dziennie |
| VMAX · Lattice Strategies Trust | 0,19% | 228 NS | 31 lipca 2026 | N-PORT |
| DSI · iShares Trust | 0,19% | 23 734 SH | 11 września 2026 | Dziennie |
| ILCV · iShares Trust | 0,18% | 5 870 SH | 10 września 2026 | Dziennie |
| IVW · iShares Trust | 0,18% | 331 185 SH | 11 września 2026 | Dziennie |
| IUSG · iShares Trust | 0,17% | 136 713 SH | 11 września 2026 | Dziennie |
| VOOG · VANGUARD ADMIRAL FUNDS | 0,17% | 115 334 SH | 19 sierpnia 2026 | Dziennie |
| IWD · iShares Trust | 0,17% | 332 035 SH | 11 września 2026 | Dziennie |
| VONV · VANGUARD SCOTTSDALE FUNDS | 0,16% | 90 157 SH | 19 sierpnia 2026 | Dziennie |
| OMFL · Invesco Exchange-Traded Self-Indexe… | 0,16% | 17 773 SH | 5 października 2026 | Dziennie |
| USMV · iShares Trust | 0,16% | 89 855 SH | 11 września 2026 | Dziennie |
| ACWV · iShares, Inc. | 0,15% | 11 903 SH | 11 września 2026 | Dziennie |
| EGLE · Global X Funds | 0,15% | 8 NS | 31 lipca 2026 | N-PORT |
| GLBL · Pacer Funds Trust | 0,15% | 4 NS | 31 lipca 2026 | N-PORT |
| PRF · Invesco Exchange-Traded Fund Trust | 0,14% | 33 331 SH | 5 października 2026 | Dziennie |
| VOXP · Advisors Series Trust | 0,13% | 18 NS | 31 lipca 2026 | N-PORT |
| VRIG · Invesco Actively Managed Exchange-T… | 0,12% | 2 250 000 | 1 października 2026 | Dziennie |
| TOPC · iShares Trust | 0,12% | 95 SH | 11 września 2026 | Dziennie |
| DGRO · iShares Trust | 0,12% | 120 741 SH | 11 września 2026 | Dziennie |
| XVV · iShares Trust | 0,11% | 1 790 SH | 11 września 2026 | Dziennie |
| QVML · Invesco Exchange-Traded Fund Trust … | 0,11% | 4 428 SH | 5 października 2026 | Dziennie |
| IWL · iShares Trust | 0,11% | 5 786 SH | 11 września 2026 | Dziennie |
| MGC · VANGUARD WORLD FUND | 0,11% | 31 176 SH | 19 sierpnia 2026 | Dziennie |
| ACIO · ETF Series Solutions | 0,11% | 6 205 NS | 31 lipca 2026 | N-PORT |
| EVUS · iShares Trust | 0,10% | 934 SH | 11 września 2026 | Dziennie |
| ADME · ETF Series Solutions | 0,10% | 751 NS | 31 lipca 2026 | N-PORT |
| XRMI · Global X Funds | 0,10% | 126 NS | 31 lipca 2026 | N-PORT |
| XCLR · Global X Funds | 0,10% | 9 NS | 31 lipca 2026 | N-PORT |
| XYLD · Global X Funds | 0,10% | 8 148 NS | 31 lipca 2026 | N-PORT |
| XTR · Global X Funds | 0,10% | 12 NS | 31 lipca 2026 | N-PORT |
| BKLC · BNY Mellon ETF Trust | 0,10% | 13 621 NS | 31 lipca 2026 | N-PORT |
| PBUS · Invesco Exchange-Traded Fund Trust … | 0,10% | 25 167 SH | 5 października 2026 | Dziennie |
| VV · VANGUARD INDEX FUNDS | 0,10% | 181 364 SH | 19 sierpnia 2026 | Dziennie |
| ESGV · VANGUARD WORLD FUND | 0,10% | 33 758 SH | 19 sierpnia 2026 | Dziennie |
| IVV · iShares Trust | 0,10% | 1 957 485 SH | 11 września 2026 | Dziennie |
| PTLC · Pacer Funds Trust | 0,10% | 7 919 NS | 31 lipca 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0,10% | 1 395 NS | 31 lipca 2026 | N-PORT |
| PBP · Invesco Exchange-Traded Fund Trust | 0,10% | 877 SH | 5 października 2026 | Dziennie |
| ILCB · iShares Trust | 0,10% | 2 915 SH | 11 września 2026 | Dziennie |
| EQAL · Invesco Exchange-Traded Fund Trust … | 0,10% | 1 794 SH | 2 października 2026 | Dziennie |
| BBUS · J.P. Morgan Exchange-Traded Fund Tr… | 0,09% | 20 766 NS | 31 lipca 2026 | N-PORT |
| IYY · iShares Trust | 0,09% | 6 693 SH | 11 września 2026 | Dziennie |
| VOTE · TCW ETF Trust | 0,09% | 2 545 NS | 31 lipca 2026 | N-PORT |
| FEX · First Trust Exchange-Traded AlphaDE… | 0,09% | 3 614 NS | 31 lipca 2026 | N-PORT |
| XYLG · Global X Funds | 0,09% | 147 NS | 31 lipca 2026 | N-PORT |
| DFUS · Dimensional ETF Trust | 0,09% | 46 791 NS | 31 lipca 2026 | N-PORT |
| IWB · iShares Trust | 0,09% | 103 721 SH | 11 września 2026 | Dziennie |
| VOO · VANGUARD INDEX FUNDS | 0,09% | 4 034 357 SH | 19 sierpnia 2026 | Dziennie |
| TOV · EA Series Trust | 0,09% | 607 NS | 31 lipca 2026 | N-PORT |
| SPUU · Direxion Shares ETF Trust | 0,09% | 586 NS | 31 lipca 2026 | N-PORT |
| ITOT · iShares Trust | 0,09% | 202 387 SH | 11 września 2026 | Dziennie |
| ACVF · ETF Opportunities Trust | 0,09% | 337 NS | 31 lipca 2026 | N-PORT |
| GTOS · Invesco Actively Managed Exchange-T… | 0,09% | 104 000 | 5 października 2026 | Dziennie |
| QDPL · Pacer Funds Trust | 0,09% | 3 708 NS | 31 lipca 2026 | N-PORT |
| IWV · iShares Trust | 0,09% | 41 034 SH | 11 września 2026 | Dziennie |
| DFAU · Dimensional ETF Trust | 0,08% | 25 516 NS | 31 lipca 2026 | N-PORT |
| CRBN · iShares Trust | 0,08% | 2 269 SH | 11 września 2026 | Dziennie |
| TOK · iShares Trust | 0,08% | 451 SH | 11 września 2026 | Dziennie |
| VTI · VANGUARD INDEX FUNDS | 0,08% | 4 930 930 SH | 19 sierpnia 2026 | Dziennie |
| VONE · VANGUARD SCOTTSDALE FUNDS | 0,08% | 24 633 SH | 19 sierpnia 2026 | Dziennie |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,08% | 12 577 SH | 19 sierpnia 2026 | Dziennie |
| PHDG · Invesco Actively Managed Exchange-T… | 0,08% | 116 SH | 5 października 2026 | Dziennie |
| HCMT · Direxion Shares ETF Trust | 0,08% | 1 081 NS | 31 lipca 2026 | N-PORT |
| TILT · FlexShares Trust | 0,08% | 4 108 NS | 31 lipca 2026 | N-PORT |
| SPXL · Direxion Shares ETF Trust | 0,07% | 12 141 NS | 31 lipca 2026 | N-PORT |
| URTH · iShares, Inc. | 0,07% | 14 079 SH | 11 września 2026 | Dziennie |
| ACWI · iShares Trust | 0,06% | 50 294 SH | 11 września 2026 | Dziennie |
| HDUS · Lattice Strategies Trust | 0,05% | 275 NS | 31 lipca 2026 | N-PORT |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0,05% | 125 729 SH | 19 sierpnia 2026 | Dziennie |
| DCOR · Dimensional ETF Trust | 0,05% | 3 816 NS | 31 lipca 2026 | N-PORT |
| GLOF · iShares Trust | 0,04% | 202 SH | 11 września 2026 | Dziennie |
| DUHP · Dimensional ETF Trust | 0,04% | 10 761 NS | 31 lipca 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0,02% | 28 662 NS | 31 lipca 2026 | N-PORT |
| DFSU · Dimensional ETF Trust | 0,02% | 1 127 NS | 31 lipca 2026 | N-PORT |
| DXUV · Dimensional ETF Trust | 0,01% | 99 NS | 31 lipca 2026 | N-PORT |
| GTO · Invesco Actively Managed Exchange-T… | 0,00% | 42 000 | 30 września 2026 | Dziennie |
| CBLS · Elevation Series Trust | -1,12% | -1 546 NS | 31 lipca 2026 | N-PORT |
| BIV · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| BLV · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| BSV · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| BND · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VUSB · VANGUARD BOND INDEX FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCRB · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VPLS · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VSDB · VANGUARD MALVERN FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCSH · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCIT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VCLT · VANGUARD SCOTTSDALE FUNDS | · | · | 15 lipca 2026 | Dziennie |
| VTC · VANGUARD SCOTTSDALE FUNDS | · | · | 30 lipca 2026 | Dziennie |
| BNDW · VANGUARD SCOTTSDALE FUNDS | · | · | 30 lipca 2026 | Dziennie |
| VCEB · VANGUARD WORLD FUND | · | · | 30 lipca 2026 | Dziennie |
HCA Konsensus analityków Bycze i niedźwiedzie opinie analityków, 12-miesięczny cel cenowy, potencjał wzrostu
12-miesięczny cel cenowy
22 analityków · 2026-10-05Średnia cel $454.23 +5,1%
Porównanie z porównywalnymi firmami (podbranża GICS) Kluczowe metryki w porównaniu do konkurentów z sektora
Podstawa R/R, ceny według zamknięcia z ostatniego końca roku obrotowego każdej spółki.
| Ticker | Kapitalizacja Rynkowa | P/E | Przychody r/r | Marża Netto | ROE | Marża brutto |
|---|---|---|---|---|---|---|
| HCA | $104.86B | 16.5 | 7.1% | 9.0% | -159.1% | · |
| THC | $17.28B | 12.8 | 3.1% | 11.1% | 56.4% | · |
| EHC | $10.61B | 19.2 | 10.5% | 9.5% | 25.1% | · |
| UHS | · | 9.4 | 9.7% | 8.6% | 21.4% | · |
| ENSG | $10.12B | 29.8 | 18.7% | 6.8% | 16.9% | · |
| PACS | $6.01B | 31.5 | 29.3% | 3.6% | 23.1% | · |
| CON | $2.53B | 15.1 | 13.9% | 7.7% | 49.8% | · |
| ACHC | $1.28B | -1.2 | 5.0% | -33.3% | -43.9% | · |
| BKD | $2.57B | -9.6 | 2.2% | -8.2% | -313.2% | 26.2% |
| SNDA | $612M | -7.7 | 25.2% | -18.6% | -197.2% | · |
Najnowsze wiadomości Najnowsze nagłówki wspominające o tej firmie
Sygnały transakcyjne Ostatnie sygnały kupna/sprzedaży z ceną wejścia i wskaźnikiem ryzyka/zysku
Obecnie brak otwartego sygnału — żadna karta nie jest wypełniona, i to jest uczciwe.
Moje wskaźniki Twoja osobista lista obserwowanych — wybrane wiersze z Pełnych Fundamentów
Wybierz wskaźniki, które są dla Ciebie ważne — kliknij + obok dowolnego wiersza w sekcji Pełne dane fundamentalne powyżej.
Twój wybór został zapisany i będzie Ci towarzyszył we wszystkich tickerach.